Greetings from Singapore     Acquisitions /mergers/joint-ventures:   Acorda Therapeutics acquires Biotie Therapies (Finland) for $362 million and gets global rights to tozadenant, an oral adenosine A2a receptor antagonist that is in late-stage clinical development for Parkinson's disease.   BioMerieux (Lyon France) spins off bioTheranostics (San Diego, CA, USA), a cancer diagnostic company, for $32 […]

Acquisitions /mergers/joint-ventures:   Shire acquires Baxalta for $32 billion in a cash-and stock deal and becomes the largest rare disease company in the world.   Merck acquires IOmet (Edinburgh, UK) and gets access to preclinical cancer candidates. IOmet will operate as a unit of Merck. Financial details were not disclosed.   Pfizer acquires Sirio Pharma’s […]

Pharma-Biotech and IVD events have been up-dated for 2016 :       Pharma-Biotech Events 2016            In vitro Diagnostic Events 2016   Please contact us if you want to be represented on a specific event or helped to prepare a business convention or meeting on a trade-show Contact us  For more info visit also the […]

  Acquisitions /mergers/joint-ventures   According to Bloomberg, Shire is in advanced talks with Baxalta (Bannockburn, Ill, USA), the biopharma spin off company of Baxter, in a deal expected to reach $32 billion. In August of 2015 Baxalta’s management had rejected an unsolicited offer by Shire worth $30 billion.   Business   Baxalta (Bannockburn, Ill, USA) and […]

CRISP Technology: Breakthrough of the Year 2015   Every December, the staff of Science singles out a significant achievement as the Breakthrough of the Year. This year they have selected CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats), occurring in the genome of certain bacteria, from which the system was discovered. CRISPR has already become a rapid and easy to use gene editing technology […]